COMP <GO>
NSRX vs LITS // EV/EBITDA & P/E VALUATION
Nasus Pharma Ltd. (NYSE) VS. Lite Strategy Inc. (NASDAQ) • 15-METRIC TALLY: NSRX 2
— LITS 2
■ METRIC PARITY
LAST: $3.19 (-4.49%) • MKT CAP: $37.4M
valuation
—
LAST: $1.17 (-4.88%) • MKT CAP: $35.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NSRX VS. LITS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NSRX | LITS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -18.90% | -16.10 | LITS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.20% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -0.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -0.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 11.68 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | NSRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.3 | 44.0 | -5.67 | LITS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.4M | $35.6M | $1.8M | NSRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NSRX REV | LITS REV | NSRX GROSS % | LITS GROSS % | NSRX FCF | LITS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $0 | — | — | -$4.9M | -$20.8M |
| FY 2024 | $0 | $65.3M | — | — | -$665.0K | -$50.5M |
| FY 2023 | $0 | $48.8M | — | — | -$1.0M | -$52.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NSRX // BETA —
LITS // BETA —